Literature DB >> 35862709

Lipid A Variants Activate Human TLR4 and the Noncanonical Inflammasome Differently and Require the Core Oligosaccharide for Inflammasome Activation.

Jasmine Alexander-Floyd1, Antonia R Bass1, Erin M Harberts2, Daniel Grubaugh3, Joseph D Buxbaum4,5,6, Igor E Brodsky3, Robert K Ernst2, Sunny Shin1.   

Abstract

Detection of Gram-negative bacterial lipid A by the extracellular sensor, myeloid differentiation 2 (MD2)/Toll-like receptor 4 (TLR4), or the intracellular inflammasome sensors, CASP4 and CASP5, induces robust inflammatory responses. The chemical structure of lipid A, specifically its phosphorylation and acylation state, varies across and within bacterial species, potentially allowing pathogens to evade or suppress host immunity. Currently, it is not clear how distinct alterations in the phosphorylation or acylation state of lipid A affect both human TLR4 and CASP4/5 activation. Using a panel of engineered lipooligosaccharides (LOS) derived from Yersinia pestis with defined lipid A structures that vary in their acylation or phosphorylation state, we identified that differences in phosphorylation state did not affect TLR4 or CASP4/5 activation. However, the acylation state differentially impacted TLR4 and CASP4/5 activation. Specifically, all tetra-, penta-, and hexa-acylated LOS variants examined activated CASP4/5-dependent responses, whereas TLR4 responded to penta- and hexa-acylated LOS but did not respond to tetra-acylated LOS or penta-acylated LOS lacking the secondary acyl chain at the 3' position. As expected, lipid A alone was sufficient for TLR4 activation. In contrast, both core oligosaccharide and lipid A were required for robust CASP4/5 inflammasome activation in human macrophages, whereas core oligosaccharide was not required to activate mouse macrophages expressing CASP4. Our findings show that human TLR4 and CASP4/5 detect both shared and nonoverlapping LOS/lipid A structures, which enables the innate immune system to recognize a wider range of bacterial LOS/lipid A and would thereby be expected to constrain the ability of pathogens to evade innate immune detection.

Entities:  

Keywords:  TLR4; caspase-4; inflammasome; lipid A; lipopolysaccharide

Mesh:

Substances:

Year:  2022        PMID: 35862709      PMCID: PMC9387229          DOI: 10.1128/iai.00208-22

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.609


  77 in total

1.  Kinetics of binding of LPS to recombinant CD14, TLR4, and MD-2 proteins.

Authors:  Han Jae Shin; Hayyoung Lee; Jong Dae Park; Hak Chul Hyun; Hyung Ok Sohn; Dong Wook Lee; Young Sang Kim
Journal:  Mol Cells       Date:  2007-08-31       Impact factor: 5.034

2.  Why have clinical trials in sepsis failed?

Authors:  John C Marshall
Journal:  Trends Mol Med       Date:  2014-02-24       Impact factor: 11.951

3.  Guanylate binding proteins promote caspase-11-dependent pyroptosis in response to cytoplasmic LPS.

Authors:  Danielle M Pilla; Jon A Hagar; Arun K Haldar; Ashley K Mason; Daniel Degrandi; Klaus Pfeffer; Robert K Ernst; Masahiro Yamamoto; Edward A Miao; Jörn Coers
Journal:  Proc Natl Acad Sci U S A       Date:  2014-04-08       Impact factor: 11.205

4.  Human Toll-like receptor 4 recognizes host-specific LPS modifications.

Authors:  Adeline M Hajjar; Robert K Ernst; Jeff H Tsai; Christopher B Wilson; Samuel I Miller
Journal:  Nat Immunol       Date:  2002-03-25       Impact factor: 25.606

5.  Noncanonical inflammasome activation by intracellular LPS independent of TLR4.

Authors:  Nobuhiko Kayagaki; Michael T Wong; Irma B Stowe; Sree Ranjani Ramani; Lino C Gonzalez; Sachiko Akashi-Takamura; Kensuke Miyake; Juan Zhang; Wyne P Lee; Artur Muszyński; Lennart S Forsberg; Russell W Carlson; Vishva M Dixit
Journal:  Science       Date:  2013-07-25       Impact factor: 47.728

6.  A live attenuated strain of Yersinia pestis KIM as a vaccine against plague.

Authors:  Wei Sun; David Six; Xiaoying Kuang; Kenneth L Roland; Christian R H Raetz; Roy Curtiss
Journal:  Vaccine       Date:  2011-02-12       Impact factor: 3.641

Review 7.  Sepsis and septic shock.

Authors:  Richard S Hotchkiss; Lyle L Moldawer; Steven M Opal; Konrad Reinhart; Isaiah R Turnbull; Jean-Louis Vincent
Journal:  Nat Rev Dis Primers       Date:  2016-06-30       Impact factor: 52.329

8.  Lipid A and immunotherapy.

Authors:  E Ribi; J L Cantrell; K Takayama; N Qureshi; J Peterson; H O Ribi
Journal:  Rev Infect Dis       Date:  1984 Jul-Aug

Review 9.  Recognition of lipid A variants by the TLR4-MD-2 receptor complex.

Authors:  Nina Maeshima; Rachel C Fernandez
Journal:  Front Cell Infect Microbiol       Date:  2013-02-12       Impact factor: 5.293

10.  GBPs Inhibit Motility of Shigella flexneri but Are Targeted for Degradation by the Bacterial Ubiquitin Ligase IpaH9.8.

Authors:  Michal P Wandel; Claudio Pathe; Emma I Werner; Cara J Ellison; Keith B Boyle; Alexander von der Malsburg; John Rohde; Felix Randow
Journal:  Cell Host Microbe       Date:  2017-10-11       Impact factor: 31.316

View more
  1 in total

1.  Position-Specific Secondary Acylation Determines Detection of Lipid A by Murine TLR4 and Caspase-11.

Authors:  Erin M Harberts; Daniel Grubaugh; Daniel C Akuma; Sunny Shin; Robert K Ernst; Igor E Brodsky
Journal:  Infect Immun       Date:  2022-07-14       Impact factor: 3.609

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.